PFS for R-GCVP and R-CEOP in patients not eligible for R-CHOP. (A) PFS in patients (n = 63) considered unfit for anthracycline-containing chemoimmunotherapy because of cardiac comorbidity treated with R-GCVP. Reprinted from Fields³⁰  with permission of the American Society of Clinical Oncology. (B) Median PFS from a single institution report of R-CEOP in patients with DLBCL (n = 26) separated into GCB and non-GCB phenotype. Reprinted from Rashidi³²  with permission of Taylor & Francis.